



# JCG Meeting Summary

## VTC

### 23 February, 2021

---

#### Attendees

- Peggy Hamburg (JCG Chair)

#### Member Institutions Represented By

- Emanuele Capobianco (IFRC)
- Marco Cavaleri (EMA)
- Mark Feinberg
- Marion Gruber (FDA)
- Ana Maria Henao Restrepo (WHO)
- Mark Page (NIBSE)
- Nandy Robin (UNICEF)
- Vasee Moorthy (WHO)
- Diadie Miaga (WHO/AVAREF)
- Aurelia Nguyen (GAVI)
- Charlie Weller (Wellcome Trust)
- Sidney Wong (MSF)
- Rogerio Gaspar (WHO)

#### Working Groups Represented By

- Daniel Brasseur (Regulatory WG)
- Murray Lumpkin (Regulatory WG)

#### CEPI Secretariat

- Luc Debruyne
- Matthew Downham
- Adam Hacker
- Richard Hatchett
- Elen Hoeg
- Frederik Kristensen
- Paul Kristiansen
- Nick Jackson
- Nicole Lurie
- Elizabeth Rinaldi
- James Robinson
- Melanie Saville
- Joseph Simmonds-Issler
- Debra Yeskey

The Joint Coordination Group met by teleconference on February 23, 2021, to discuss the updates and progress of the CEPI's core vaccine portfolio, and to introduce and get feedback on the CEPI 2.0 planning.

## **JCG Member Roundtable discussion**

Peggy Hamburg (JCG Chair) welcomed the group. Members introduced themselves and summarized their current activities, almost all of which related to their intensive work on COVID. Topics of concern include:

- i) Supply bottlenecks and supply chain shortages with attention to the impact on the global supply chain and delay implications;
- ii) Emergence and future handling of emerging variants;
- iii) and, the use of vaccines not approved by the World Health Organization or other stringent regulatory bodies.

Members also celebrated each other's work and successes with attention given to the overall advancement of science and the acceleration of research and development during the pandemic.

## **CEPI's Core Vaccine Portfolio**

CEPI's Nick Jackson, presented updates on CEPI's Core Vaccine portfolio. Lassa and Nipah vaccines have entered human trials, which are important milestones. Chick vaccines are in Phase 3. Attention was paid to CEPI's Ebola work as outbreaks have recently emerged in Guinea and The Democratic Republic of the Congo. CEPI is supporting a trial of the JnJ vaccine in pregnant women. Ana Maria Henao Restrepo, briefly updated the group on the WHO's response to the outbreak and the vaccine mobilization efforts in those areas. (slides attached)

## **Summary of CEPI's COVID Activities**

Melanie Saville presented an update and summary of CEPI's COVID activities and recapped CEPI's strategy on variants. CEPI is committed to the continuation of investment and support of the COVAX R&D portfolio and the optimization of equitable access for vaccines in the COVAX facilities. (slides attached)

## **CEPI 2.0**

Frederik Kristensen, Deputy CEO, introduced the group to CEPI 2.0 plans to date. The strategy of CEPI 2.0 is to prepare for known pandemic threats, transform response, and connect and foster global collaboration to ensure a systematic reduction of risk for future epidemic and pandemic threats. CEPI 2.0 has also begun to articulate what conditions need to be in place globally (outside of CEPI) for CEPI to be fully successful. Members provided feedback on the plans for CEPI 2.0, including the suggestion to further clarify what CEPI's unique role in the ecosystem was, and what CEPI would deliver in its second 5 years.

## **Conclusion**

JCG members will continue to provide feedback, as well as to consider how the JCG should evolve as the pandemic comes under control and we consider how to build on learnings from COVAX and ACT-A. Timing of the next meeting will be somewhat dependent on the pandemic. Meanwhile, CEPI leadership will follow up with 1:1 discussions with JCG members to seek further input into next steps.